VNDA—(+16%)—reports phase-2 data_in suppression of GLP_1 nausea/vomiting: https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-positive-results-for-tradipitant-in-preventing-glp-1-induced-nausea-and-vomiting-302617739.html https://www.clinicaltrials.gov/study/NCT06804603